FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / News / Read News

Print

Runway Growth Capital Provides Up to $65MM Credit Facility to SetPoint Medical

January 20, 2023, 07:55 AM
Filed Under: Healthcare

SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced a senior secured term loan facility of up to $65 million from Runway Growth Capital LLC. The loan is an expansion of an existing credit facility with Runway. The company recently announced an $80 million equity financing to advance its novel platform for the treatment of autoimmune disease.

The funds will be used to complete the ongoing RESET-RA study and subsequent U.S. Food and Drug Administration (FDA) regulatory submissions and early commercialization for the company’s rheumatoid arthritis (RA) indication. The SetPoint system is designed for patients with RA who have incomplete response to or are intolerant to biologic drugs. The system consists of a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure. The vagus nerve stimulation activates innate anti-inflammatory pathways on a preset schedule.

“We are pleased to continue our relationship with Runway,” said Murthy V. Simhambhatla, Ph.D., President and CEO of SetPoint Medical. “This non-dilutive debt financing provides additional support and flexibility as we advance our mission and progress toward completing the RESET-RA study. We are confident that we have the right lender and partner to advance the development and early commercialization of our novel therapeutic platform for patients with chronic autoimmune conditions.”

“We are excited to support SetPoint Medical and partner with such a forward-thinking company in the chronic autoimmune disease space,” said Igor DaCruz, Managing Director, Life Sciences, Runway Growth Capital. “Runway believes the SetPoint Medical team is well positioned to improve the lives of patients and their families, who in many cases may have exhausted their biologic options for relief.”








Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.